{"nctId":"NCT00474786","briefTitle":"Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib","startDateStruct":{"date":"2007-09"},"conditions":["Renal Cell Carcinoma"],"count":512,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Sorafenib"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: temsirolimus (Torisel)"]}],"interventions":[{"name":"Sorafenib","otherNames":[]},{"name":"temsirolimus (Torisel)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy status) with well-documented Radiological PD by RECIST criteria or clinical PD as judged by the investigator while receiving first-line sunitinib therapy. Subjects must have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).\n* At time of randomization, at least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery.\n* At time of randomization, there must be at least 1 measurable lesion per RECIST. Lesions that have been previously irradiated or embolized cannot be selected as target lesions.\n\n  * More criteria apply\n\nExclusion Criteria:\n\n* Metastatic CNS from RCC.\n* Subjects who discontinued Sutent therapy due specifically to intolerance.\n* Prior systemic therapy for mRCC other than sunitinib.\n* Active ketonuria, secondary to poorly controlled diabetes mellitus\n\n  * More criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"Interval from date of randomization until documentation of progressive disease (PD) by an independent tumor assessment according to Response Evaluation Criteria in Solid Tumor (RECIST) or death for any reason whichever occurred first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":null},{"groupId":"OG001","value":"3.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) by Investigator Assessment","description":"Interval from date of randomization until documentation of PD by an investigator tumor assessment, symptomatic deterioration, or death for any reason whichever occurred first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.43","spread":null},{"groupId":"OG001","value":"4.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Tumor Response","description":"Percentage of participants with tumor response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST and evaluated by independent central review. CR/PR persisted on repeat imaging study at least 4 weeks after initial documentation of response. PR had at least 30 percent decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.27","spread":null},{"groupId":"OG001","value":"16.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment","description":"PFS: Interval from date of randomization until documentation of PD by an independent tumor assessment according to RECIST or death for any reason whichever occurred first. PFS calculated as (Weeks)=(randomization date minus first dose date plus 1) divided by 7.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DR)","description":"Duration of response as defined by the time from CR or PR (whichever status recorded first) until the date of death or PD was objectively documented. Median and its 95 percent confidence interval (95% CI) were estimated using Kaplan-Meier method.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.26","spread":null},{"groupId":"OG001","value":"6.96","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to \\[study drug\\] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"251","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":104,"n":249},"commonTop":["Diarrhoea","Rash","Fatigue","Decreased appetite","Nausea"]}}}